Jeito Capital, a biopharma-focused private equity firm, has raised $1.2 billion for its latest fund to deploy money into clinical-stage companies in Europe, tapping into increased investor interest from the US.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.